ankyrin repeat and death domain containing 1BGenealiases: []
Q-omics provides the consensus-scored ANKDD1B profile across patient tissues and cancer cell-line models. ANKDD1B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ANKDD1B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ANKDD1B RNA expression shows 18,814 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, COAD, and THYM as cancer lineages where ANKDD1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKDD1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKDD1B survival associations across molecular data types. ANKDD1B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKDD1B RNA expression–survival associations across cancer types. High ANKDD1B expression shows unfavorable associations in LGG, CESC and THCA, but favorable associations in KIRP, COAD and READ. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ANKDD1B RNA expression.
This table summarizes ANKDD1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANKDD1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKDD1B shows lower tumor expression in COAD, LUSC, BRCA and KIRC and higher tumor expression in CHOL and THCA. The COAD box plot shows higher ANKDD1B RNA expression in normal versus tumor tissue (log2 FC = −0.675, t-test p < 0.001).
This table shows molecular features associated with ANKDD1B in patient tissues and cancer cell lines. In patient samples, ANKDD1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKDD1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
